Bellevue Group AG grew its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Free Report) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,535,839 shares of the company’s stock after buying an additional 400,000 shares during the quarter. Bellevue […]
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment .
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment